BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 14551738)

  • 1. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
    Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
    Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
    Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
    Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia.
    Henzan H; Yoshimoto G; Okeda A; Nagasaki Y; Hirano G; Takase K; Tanimoto T; Miyamoto T; Fukuda T; Nagafuji K; Harada M
    Ann Hematol; 2004 Dec; 83(12):784-8. PubMed ID: 15322764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24).
    Lennon PA; Abruzzo LV; Medeiros LJ; Cromwell C; Zhang X; Yin CC; Kornblau SM; Konopieva M; Lin P
    Cancer Genet Cytogenet; 2007 Aug; 177(1):37-42. PubMed ID: 17693189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia.
    Ohyashiki K; Ohyashiki JH; Fujieda H; Shimamoto T; Kawakubo K; Nakazawa S; Suzukawa K; Morishita K; Toyama K
    Leukemia; 1994 Dec; 8(12):2169-73. PubMed ID: 7808006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
    Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
    Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
    Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
    De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
    Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
    Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
    Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.
    Poppe B; Dastugue N; Vandesompele J; Cauwelier B; De Smet B; Yigit N; De Paepe A; Cervera J; Recher C; De Mas V; Hagemeijer A; Speleman F
    Genes Chromosomes Cancer; 2006 Apr; 45(4):349-56. PubMed ID: 16342172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
    Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C; Rowley JD; Nucifora G
    Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
    Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
    Bobadilla D; Enriquez EL; Alvarez G; Gaytan P; Smith D; Slovak ML
    Br J Haematol; 2007 Mar; 136(6):806-13. PubMed ID: 17341266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
    De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
    Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements.
    Madrigal I; Carrió A; Gómez C; Rozman M; Esteve J; Nomdedeu B; Campo E; Costa D
    Cancer Genet Cytogenet; 2006 Oct; 170(2):115-20. PubMed ID: 17011981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.